Tempus AI Inc (TEM)

As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the DataJuly 1, 2026 9:00 AM
PR Newswire (Canada) Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ: HYFT) filed a foundational European patent application covering the multi-dimensional data architecture at the core of its HYFT® Technology, an attempt to protect, at the architectural level, the enriched biological data layer that its commercial platforms run on.NEW YORK, July 1, 2026 /CNW/ -- USA News Group, There is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable, and that lasting competitive advantage is shifting away from the model and toward the proprietary, structured data a model reasons over. On that thesis, MindWalk Holdings Corp. (NASDAQ: HYFT) has just made a defining move, filing a foundational European patent application covering the multi-dimensional data structure at the core of its proprietary HYFT® Technology. Key TakeawaysMindWalk Holdings Corp. (NASDAQ: HYFT), a Bio-Native AI company, filed a foundational patent application with the European Patent Office (Application No. EP26187897.9) covering the multi-dimensional data structure at the core of its proprietary HYFT® Technology.The filing is built on a thesis gaining traction across enterprise AI: as frontier models converge toward commodity, durable advantage migrates to the data layer, the structured, domain-specific representation a model reasons over.The patented architecture powers MindWalk's ReefIQ™ biological context layer and LensAI™ platform, the latter already in contracted, recurring arrangements with life-sciences customers.MindWalk is moving in the same data-and-platform direction as other public life-sciences AI names, including Tempus AI (NASDAQ: TEM), AbCellera (NASDAQ: ABCL), Schrödinger (NASDAQ: SDGR), and Recursion (NASDAQ: RXRX), each distinct, and none a proxy for MindWalk.Patenting the Moat, Not the ModelThere is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable. As frontier systems from competing labs converge on similar capabilities, the place where lasting competitive advantage accrues is shifting, away from the model and toward the proprietary, structured data the model is given to reason over. On that thesis, MindWalk Holdings Corp. (NASDAQ: HYFT) has just made a defining move: the Austin-based Bio-Native AI company announced it filed a foundational patent application with the European Patent Office (Application No. EP26187897.9) covering the multi-dimensional data structure at the heart of its proprietary HYFT® Technology.The intent, in the company's framing, is to protect at the architectural level the enriched biological representation that underpins its commercial platform, the asset MindWalk regards as its core, compounding competitive advantage. In other words, rather than racing to build a better model, MindWalk is moving to fence off the data layer beneath the models. The company's position is blunt: the competitive question in its market is not which AI model a customer runs, because every model trends toward commodity, it is what the model runs on.What the Patent Actually DescribesThe application, titled "Hyperdimensional Vector Data Structures for Biological Subsequences and Property Inference," describes a specific and unusual approach to organizing biological data. In conventional pipelines, sequence identity, learned embeddings, and biological annotations are scattered across separate tables that must be joined together at the moment of a query. MindWalk's structure instead encodes each short biological subsequence together with the properties that define its behavior, as coordinates of a single object in a space of at least 2,000 dimensions.Per the filing, that single self-contained object carries a biological subsequence alongside at least 50 heterogeneous properties, including structural data, microenvironmental geometry, functional annotations, contextual associations, and metadata. The application further describes a database of at least 600 million such records, and a method that performs vector-space operations across them to infer additional biological properties. A central claimed concept the company calls the "reduced combinatory number" identifies the subsequences most constrained in their biological context, and therefore the most informative to store and analyze. The practical claim is that the indexable unit is itself biologically meaningful, rather than an opaque vector, which, MindWalk argues, is what allows AI models and autonomous agents to reason over biology reliably rather than guess at it.The company is careful to define the architecture by what it is not: it describes the approach as alignment-free and not dependent on any single AI model, and distinct from a sequence-alignment system, a k-mer index, a motif library, or an embedding-only method, each of which, in its telling, discards either biological meaning or semantic structure. The distinction the filing is meant to protect is that its indexable unit carries both.Why the Data Layer Is Where Value Is MigratingThe strategic logic tracks a broader shift in enterprise AI. When any well-funded competitor can license or build a capable model, the model stops being a differentiator. What cannot be easily replicated is a deep, structured, domain-specific dataset built over many years, the context that makes a general model useful in a specialized field. MindWalk says it spent more than two decades curating exactly such a layer for the life sciences, and the patent filing is the move to make that architecture defensible rather than merely valuable.The market context the company cites is substantial. By MindWalk's account, drawing on third-party estimates, spending on AI in drug discovery is projected to grow from roughly US$5 billion in 2026 to more than US$8 billion by 2030, and that spend sits atop the more than US$250 billion the pharmaceutical industry invests in research and development each year. The company is positioning its data layer as infrastructure beneath that spending. As with any market-sizing, those figures are third-party projections that may prove inaccurate, and the company flags them as context only.How the Patent Connects to RevenueThe filing is not an abstract science-project claim; it sits directly beneath products the company is already commercializing. The same enriched representation powers ReefIQ™, which MindWalk describes as a biological context layer for life sciences, and the LensAI™ platform that runs on it for target discovery, candidate diligence, and portfolio decision support, the kind of agentic AI workflows pharmaceutical companies are racing to deploy. Critically, the company states that LensAI is already in contracted, recurring arrangements with life-sciences customers today. The patent is intended to place foundational IP protection around the layer those deployments depend on, an asset MindWalk says compounds in analytical value as more data accumulates on the platform.By the company's description, its HYFT® Technology underpins a continuously evolving biological representation of roughly 660 million biological patterns and 25 billion relationships, refined over 20 years of curation, that enriches data at ingestion. The filing follows MindWalk's June 2026 launch of ReefIQ and, the company says, extends a deliberate strategy of making the biological representation, not any individual AI model, the durable, compounding asset.The Public Company Cohort Investors Are WatchingMindWalk would be an unusual pure-play on the "data layer" thesis, but several public life-sciences AI companies illustrate the broader move toward proprietary data and platform moats. These comparisons are for context only; each company pursues a different technology and business model, several are far larger or further along, and none is a proxy for MindWalk or implies any partnership or comparable performance. Tempus AI (NASDAQ: TEM) is the closest thematic mirror: its competitive advantage rests on a proprietary multimodal clinical-and-molecular dataset measured in hundreds of petabytes, and it has reported strong net revenue retention as biopharma customers build on that data, a real-world example of data-as-moat in life sciences. AbCellera (NASDAQ: ABCL) runs an antibody-discovery platform monetized across a large base of partnered programs, illustrating the platform-and-partnership model rather than a single-drug bet.Schrödinger (NASDAQ: SDGR) approaches the field from physics-based computational simulation, combining a software platform used by thousands of researchers with its own drug-development programs, the established, software-led end of the spectrum. And Recursion (NASDAQ: RXRX) is among the most visible "TechBio" names, pairing large proprietary experimental datasets and an AI platform with major pharma collaborations and an internal clinical pipeline, while remaining clinical-stage and pre-profit. Together these names sketch a sector being repriced around proprietary data, platforms, and partnerships, the same terrain MindWalk's patent filing stakes a claim on, even as each company's outcome rests on its own execution.The Bottom LineA patent application is a beginning, not a guarantee. European examination can narrow or reject claims, and the scope, issuance, and enforceability of any patent that ultimately issues remain open questions the company itself flags. But the strategic signal is clear and coherent: MindWalk is betting that in a world of commodity AI models, the lasting value in life-sciences AI lives in the structured biological data underneath, and it is moving to protect its version of that layer at the architectural root. For investors tracking where durable advantage accrues as the AI buildout matures, MindWalk's filing is a concrete data point in a much larger debate, with the patent's prosecution, customer adoption, and revenue trajectory the markers worth watching from here.SIGNAL OVER NOISESignal over noise. Biotech, artificial-intelligence, and drug-discovery headlines move fast, and the crowd often moves first. Eagle Eye is a real-time investor signal-intelligence platform that surfaces sentiment shifts, news flow, and trending tickers as they happen, so you see the move forming instead of reading about it later. See it at eagle-eye.dev.CONTACTUSA News Groupinfo@usanewsgroup.comSOURCES[1] MindWalk Holdings Corp., "MindWalk Files Foundational Patent on the Multi-Dimensional Data Architecture at the Core of HYFT® Technology" (Business Wire, 2026; EPO Application No. EP26187897.9; ReefIQ/LensAI; 660M patterns / 25B relationships).[2] Tempus AI, Inc. (NASDAQ: TEM), Form 8-K and 2025 results (data-and-applications business, net revenue retention), 2026.[3] AbCellera Biologics Inc. (NASDAQ: ABCL), corporate and partnership disclosures, 2026.[4] Schrödinger, Inc. (NASDAQ: SDGR), platform and pipeline disclosures, 2026.[5] Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), Q1 2026 results and corporate disclosures, 2026.[6] AI-in-drug-discovery market estimates (Fortune Business Insights; Astute Analytica) and pharmaceutical R&D spending (Fierce Biotech; Statista), cited for context.DISCLAIMERNothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by USA News Group on behalf of Market IQ Media Group Limited, a company incorporated under the laws of Ireland ("MIQL"). MIQL has been paid a fee for MindWalk Holdings Corp. advertising and digital media from Creative Direct Marketing Group ("CDMG"). There may be 3rd parties who may have shares of MindWalk Holdings Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. MIQL and its owner/operators do not own any shares of MindWalk Holdings Corp., but reserve the right to buy and sell shares of MindWalk Holdings Corp. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQL has been reviewed and approved on behalf of MindWalk Holdings Corp. by CDMG. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.FORWARD-LOOKING STATEMENTS: This publication contains forward-looking statements, including statements regarding European patent application No. EP26187897.9 and the prosecution, scope, issuance, enforceability, and competitive value of any patent that may issue; the role of the patented architecture in HYFT® Technology, ReefIQ™, and the LensAI™ platform; the size, growth, and addressability of the markets referenced; the pace and degree of customer and market adoption of the Company's infrastructure; and the technical performance of AI-based discovery methods. Forward-looking statements are subject to known and unknown risks and uncertainties, including that patent claims may be narrowed, rejected, or successfully challenged; that third-party market estimates may prove inaccurate; and competitive, regulatory, technical, and capital-markets risks, that could cause actual results to differ materially. Additional information is available in MindWalk's Annual Report on Form 20-F and other filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov/edgar). Except as required by law, the Company undertakes no obligation to update any forward-looking statement. References to other companies are based on those companies' public disclosures, are provided for industry context only, and do not imply any partnership, endorsement, affiliation, or comparable performance. HYFT® is a registered trademark, and LensAI™ and ReefIQ™ are trademarks, of MindWalk Holdings Corp. or its subsidiaries. View original content to download multimedia:https://www.prnewswire.com/news-releases/as-ai-models-become-commodities-one-bio-native-ai-company-just-moved-to-patent-the-thing-that-actually-compounds-the-data-302815033.html Original: As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data

16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart GapJune 16, 2026 9:11 AM
PR Newswire (US) Issued on behalf of Ventripoint Diagnostics Ltd.As the number of people living with congenital heart disease climbs and most patients in poorer regions go without timely care, a Toronto-based AI imaging company is joining a new global alliance built to close that gap.TORONTO, ON, June 16, 2026 /PRNewswire/ -- Equity Insider News Commentary — Congenital heart disease is the most common birth defect in the world, and the population living with it is growing, not shrinking. According to the World Heart Federation's World Heart Report 2026, congenital heart disease now affects roughly 2% of live births globally, and the number of people living with the condition has climbed to an estimated 16 million worldwide — up from 11.8 million three decades ago. Yet the same report found that more than 90% of children in lower- and middle-income countries lack timely access to congenital heart disease care. It is a paradox at the heart of modern medicine: better treatment is keeping more patients alive and aging into adulthood, even as access to the diagnostics and monitoring they need remains deeply unequal. Companies mentioned: Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTCQB: VPTDF), HeartFlow, Inc. (Nasdaq: HTFL), Butterfly Network, Inc. (NYSE: BFLY), Tempus AI, Inc. (Nasdaq: TEM), iRhythm Technologies, Inc. (Nasdaq: IRTC)Into that gap steps a coordinated industry response — and a company positioning its technology at the center of it. On June 15, 2026, Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTCQB: VPTDF), a pioneer in advanced AI-assisted cardiac imaging, announced its support for the newly forming Global Congenital Heart Disease Alliance (GCHDA), an industry alliance dedicated to accelerating the development, commercialization, and global adoption of congenital cardiovascular technologies. As part of its initial efforts, the alliance said it would help fund and place four of Ventripoint's VMS+™ cardiac imaging units to directly support the congenital heart disease community and expand access to advanced diagnostic care.Why Congenital Heart Disease Is a Uniquely Hard ProblemCongenital heart disease is not a single condition but a broad family of structural heart defects present from birth, ranging from minor to life-threatening. What makes it uniquely challenging from a diagnostic standpoint is twofold. First, it is a lifelong condition: thanks to decades of surgical and medical advances, the vast majority of children born with congenital heart defects now survive into adulthood, creating a large and growing population that requires structured, individualized follow-up for the rest of their lives. Second, the anatomy is often complex and irregular — hearts that have been surgically reconstructed or that developed abnormally do not conform to the neat geometric assumptions built into many conventional imaging tools, making accurate measurement genuinely difficult.That combination — a lifelong need for precise, repeated monitoring against anatomy that resists easy measurement — is exactly where imaging technology matters most. The European Society of Cardiology's guidelines for adult congenital heart disease identify the condition as a chronic illness requiring lifelong individualized follow-up, and affirm echocardiography as the key modality for longitudinal assessment of heart function. The problem is that the gold standard for the most accurate measurements, cardiac MRI, is expensive, slow, and scarce — especially in the underserved regions where the access gap is widest. The field has long needed a way to get high-accuracy cardiac measurement to the point of care, without an MRI suite.Ventripoint's Approach: MRI-Level Accuracy From a Standard EchoVentripoint's flagship platform, VMS+™, is built squarely around that need. The technology uses artificial intelligence to transform standard 2D echocardiograms — among the most widely available imaging exams in the world — into highly accurate 3D models of all four chambers of the heart, delivering what the company describes as cardiac-MRI-level measurement accuracy at the point of care. For congenital heart patients, whose complex anatomy often defeats traditional imaging, that capability is especially relevant. The platform is powered by Ventripoint's proprietary Knowledge-Based Reconstruction technology, the product of roughly a decade of development, and is designed to run on existing ultrasound systems from any vendor — meaning hospitals and clinics can expand advanced cardiac imaging without buying new scanners.Crucially for a company addressing a global access gap, VMS+™ carries regulatory clearances in the United States, Europe, and Canada, and beyond congenital heart disease it supports applications including pulmonary hypertension and cardiotoxicity monitoring in oncology patients. The technology has been recognized with a Gold Medal at the 2026 Edison Awards in the Precision Health Technologies category, and has been implemented or evaluated at leading institutions including the Peter Munk Cardiac Centre in Toronto and in clinical studies at the Mayo Clinic. "Congenital heart disease affects patients across every stage of life, from infancy through adulthood," said Joe Hostetter, Director of the CHD Program at Ventripoint, framing accurate, accessible imaging as a necessary part of closing the global care gap.What the GCHDA Membership SignalsThe alliance itself is a notable development for a field that has historically been fragmented. The GCHDA describes itself as a hybrid industry association and innovation consortium, bringing together industry partners, clinicians, researchers, regulators, investors, and patient communities to accelerate congenital cardiovascular technologies through membership and advocacy programs, multi-center research collaboration, and a convening platform of summits and innovation showcases. "We exist to bring focused attention and determined project execution to the congenital heart disease community," said Julia Friesen, Executive Director of the alliance, noting that its initial efforts include funding and placing four VMS+ units to expand access to advanced diagnostic care.For Ventripoint, the value is twofold: a direct commercial signal in the planned placement of four units, and a strategic position inside a consortium that could shape how congenital cardiovascular technologies are researched, validated, and adopted worldwide. The company plans to participate in the alliance's programming, including its annual summit and innovation showcases. It is the kind of ecosystem play that, if the alliance gains traction, could give a small-cap imaging company outsized visibility among the clinicians and institutions that drive adoption — though, as with any newly forming organization, the alliance's ultimate impact remains to be proven.A Booming Market for Smarter Cardiac ImagingVentripoint is operating in one of the fastest-growing corners of medical technology. The market for artificial intelligence in cardiology has been projected to grow from roughly US$2.78 billion in 2026 to as much as US$14.2 billion or more by the mid-2030s, reflecting compound annual growth rates north of 20%. Echocardiography — the single most widely used cardiac imaging modality in the world — is itself forecast to expand to around US$2.64 billion by 2030, and portable, point-of-care ultrasound is pushing cardiac assessment out of dedicated imaging labs and into clinics and remote settings. The through-line across all of these trends is a demand for technologies that deliver clinical accuracy and economic value at once. Looking at a few of the public companies attacking adjacent parts of this market helps frame both the opportunity and the competitive landscape.HeartFlow, Inc. (Nasdaq: HTFL) is among the clearest public proxies for AI-driven cardiac imaging. The company's technology uses AI to create personalized 3D models of a patient's coronary arteries from standard CT scans to help diagnose and manage coronary artery disease non-invasively. Having gone public in 2025 and built a multibillion-dollar market capitalization, HeartFlow demonstrates the commercial scale that AI-based cardiac imaging can reach — and, like Ventripoint, it is built on the premise of replacing or deferring more invasive or expensive procedures with smarter software-driven imaging.Butterfly Network, Inc. (NYSE: BFLY) maps most directly to Ventripoint's point-of-care thesis. Butterfly makes a handheld, semiconductor-based ultrasound probe paired with AI software, pushing cardiac and other imaging out of the lab and into emergency, primary-care, and remote settings. As a company explicitly focused on democratizing access to ultrasound imaging, Butterfly illustrates the same core idea animating Ventripoint — bringing advanced imaging to wherever the patient is — albeit through hardware rather than vendor-agnostic software.Tempus AI, Inc. (Nasdaq: TEM) represents the scaled, AI-driven diagnostics platform end of the market. While best known for precision oncology, Tempus has expanded into cardiology — including an FDA-authorized ECG algorithm that has drawn CMS reimbursement — and exemplifies how richly investors are valuing AI-enabled diagnostics with reimbursement pathways and large data ecosystems. It is far larger and broader than Ventripoint, but it underscores the market's appetite for AI that turns routine tests into higher-value clinical insight.iRhythm Technologies, Inc. (Nasdaq: IRTC) rounds out the group as an established success story in AI-driven cardiac diagnostics. Its Zio platform pairs wearable ECG monitors with AI analysis to detect arrhythmias, and the company has built a substantial commercial franchise around turning continuous cardiac data into actionable diagnoses. iRhythm shows that a focused, AI-centric cardiac diagnostics company can scale into a major player — a potential template for what a technology like VMS+™ might aspire to in its own niche. These companies are referenced to illustrate the sector and do not imply any partnership, endorsement, affiliation, or comparable financial performance; they differ widely in size, technology, and stage, and Ventripoint is among the smaller, earlier-stage names.The Investment Lens: Promise and CaveatsThe appeal of Ventripoint's positioning is easy to see. It has a regulatory-cleared, vendor-agnostic technology that addresses a real and growing clinical need; recognition from clinicians and awards bodies; implementations at respected cardiac centers; and now a seat inside a global alliance with a concrete near-term order for four units. In a market racing toward AI-enabled, point-of-care cardiac imaging, those are meaningful assets, and the congenital heart disease angle gives the company both a humanitarian narrative and a defensible clinical niche where its accuracy advantage matters most.The caveats are equally important. Ventripoint is a small-cap company in the capital-intensive, slow-moving world of medical technology, where adoption cycles are long, hospital procurement is deliberate, and revenue can take years to scale even for clinically validated products. The GCHDA is newly forming, and the placement of four units — while a positive signal — is modest in absolute terms; the alliance's broader promise is, for now, potential rather than proven. The company competes, directly or indirectly, against far larger and better-funded players, and like most small-cap medtechs it faces ongoing financing needs and the risks that come with them. Investors should weigh the genuine clinical merit and strategic positioning against the realities of commercialization at small scale.Why the Trajectory Still MattersStep back, and the larger picture is compelling regardless of any single company's fortunes. The global population living with congenital heart disease is growing, the need for lifelong monitoring is intensifying, the access gap in much of the world remains vast, and the technology to deliver accurate cardiac measurement at the point of care — without an MRI suite — is maturing rapidly. The formation of a dedicated global alliance to coordinate the field's fragmented efforts is itself a sign that the problem is finally drawing focused, cross-sector attention. Ventripoint has placed itself, and its AI imaging platform, squarely inside that movement.Whether the company can convert clinical validation, awards, and alliance membership into durable commercial scale is the question that will define its future, and the path for any small-cap medtech is rarely smooth. But the direction of the field is unmistakable: toward smarter, cheaper, more accessible cardiac imaging, and toward coordinated global efforts to bring it to the millions of congenital heart disease patients who currently go without. For investors tracking where AI meets the future of cardiac care, Ventripoint's latest move is a small but telling marker of that broader shift.CONTINUED … Learn more about Ventripoint Diagnostics Ltd. at: https://usanewsgroup.com/vpt-landing/SEE WHAT THE MARKET IS TALKING ABOUT BEFORE IT MOVESEagle Eye reads social, forum, and news chatter across thousands of investor conversations in real time — and surfaces the tickers the crowd is piling into, along with the sentiment and catalysts behind them.Explore Eagle Eye free (for now) at https://Eagle-Eye.devCONTACT:Equity Insiderinfo@equity-insider.comSOURCES:[1] Ventripoint Diagnostics Ltd. — "Ventripoint Diagnostics Announces Support for the Global Congenital Heart Disease Alliance" (TheNewswire, June 15, 2026; primary source for the GCHDA support, four VMS+ units, VMS+™ description, WHF 2026 data, management quotes):
https://www.ventripoint.com/news[2] World Heart Federation — World Heart Report 2026 (CHD ~2% of live births; ~16 million people living with CHD, up from 11.8 million; >90% of children in LMICs lack timely CHD care):
https://world-heart-federation.org/world-heart-report-2026/[3] Investing News Network — "Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts" (AI-in-cardiology market ~US$2.78B 2026 to ~US$14.22B; echocardiography ~US$2.64B by 2030; 2020 ESC ACHD guidelines; peer context):
https://investingnews.com/cardiac-ai-diagnostics-stack-validation-wins-across-regulatory-and-commercial-fronts/[4] Ventripoint Diagnostics Ltd. / Providence Health Care Ventures — St. Paul's Hospital VMS+™ validation collaboration (FDA-cleared and Health Canada-licensed; runs on existing ultrasound; Peter Munk and Mayo Clinic implementations):
https://phcventures.ca/phc-ventures-ventripoint-ai-cardiac-imaging/[5] HeartFlow, Inc. — Nasdaq listing and AI coronary imaging overview (peer context: HTFL, BFLY, TEM, IRTC public cardiac-imaging / cardiac-AI names):
https://www.nsf.gov/science-matters/heartflows-ai-powered-medical-technology-debuts-nasdaqDISCLAIMER:Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content to download multimedia:https://www.prnewswire.com/news-releases/16-million-people-one-underserved-disease-the-ai-imaging-push-to-close-the-congenital-heart-gap-302800970.html Original: 16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap

Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 5, 2026 4:01 PM
Business Wire Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Tempus Founder and CEO Eric Lefkofsky will participate in a fireside chat at 2:00 p.m. ET on Monday, June 8. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260605552468/en/ Hanah Heintzelman
hanah.heintzelman@tempus.com Original: Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug DevelopmentMay 31, 2026 8:30 AM
Business Wire Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform designed to accelerate drug development and research. This evolution seamlessly connects Tempus’ multimodal data, AI tooling and computational infrastructure to deliver actionable insights at the pace required for drug development. The next-generation of the Lens platform is built on over a decade of longitudinal real-world data and years of expertise translating that data into actionable evidence for biopharma. Lens combines one of the world's largest real-world multimodal datasets, high-performance AI computing, Tempus’ oncology foundation models, validated AI agents, and scientific workflows, all integrated into a single platform. The platform was purpose-built to enable drug development teams to design better clinical trials, target patient subgroups faster, and generate critical evidence in a fraction of the time. Lens is commercially available today via lens.tempus.ai and is already utilized by a rapidly expanding user base, including 19 of the top 20 largest biopharma companies. The multi-agent platform is designed to deliver a seamless, end-to-end experience through several specialized tools: Custom Research Plan Generation: Lens Co-scientist agents have deep context on the Tempus RWD model and datasets available within a project, and are grounded in oncology knowledge for insight generation. Users can propose complex biological hypotheses using plain language and receive a targeted analysis plan that can be refined seamlessly by collaborating directly with the agent. On-Demand Execution: Once a plan is finalized, the agent executes the analysis in code against Tempus’ massive multimodal library—including more than 8.5 million queryable de-identified patient records—to deliver robust, code-backed results in minutes. Specialized AI Agents: Custom-validated agents designed to support common use cases of real-world data, such as biomarker validation and trial design support agents, are optimized for specific phases of drug development and translational workflows. Reproducible Intelligence: Results are delivered via interactive, shareable applications and reports. For deep validation and full transparency, users can instantly toggle to a “code” view to audit the underlying analytical logic or export the entire project to a private Workspace for further technical extension. "Drug development requires thousands of pivotal decisions between molecule and approval, and at its core, it is a navigation problem—most paths end in dead studies and wasted capital, which is why the industry needs a fundamentally different approach," said Ryan Fukushima, CEO of Data and Apps at Tempus. "Real-world multimodal data is complex, and turning it into decisions has historically required too much domain and data science expertise, resulting in weeks or months of manual analysis. The next generation of Lens consolidates this workflow into a single platform, with Tempus One serving as a co-scientist that does much of the heavy lifting. We've tuned every layer of the platform to empower biopharma teams to see the optimal development path clearly and make critical decisions faster than ever before." For more information, including how to access Lens, please visit: lens.tempus.ai. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and benefits of Lens, including but not limited to features designed to accelerate drug development and research. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260531652876/en/ Hanah Heintzelman
hanah.heintzelman@tempus.com Original: Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research CommunityMay 30, 2026 8:30 AM
Business Wire Inaugural program provides unprecedented access to Tempus’ library of de-identified multimodal data and models, scalable compute infrastructure and direct funding to catalyze clinical and technical breakthroughs Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the PRECISION Challenge, a national initiative engineered to accelerate the next generation of oncology breakthroughs leveraging its foundational model. The PRECISION Challenge aims to unlock breakthroughs in oncology at scale by providing access to data, funding, and expertise to multidisciplinary teams around the world who seek to make bold advances in cancer treatment and improve patient outcomes. The PRECISION Challenge will provide selected participants with an unprecedented ecosystem of resources, combining direct financial funding with scientific and analytical infrastructure. Program recipients will gain structured access to Tempus’ proprietary, de-identified data library—one of the world's largest repositories of clinical, molecular, and imaging data—alongside a suite of Tempus’ foundation models, agentic tooling, and compute infrastructure in the Lens Workspaces environment, designed to accelerate biological discovery from multimodal real world data. As part of the PRECISION Challenge, Tempus and a group of external advisors will identify specific clinical and technical challenges for the research community to address, focused on advancing precision medicine in oncology by leveraging Tempus’ large multimodal foundation model. The program will provide staged funding and compute resources tied to research milestones and demonstrated progress: Proof of Concept Grant: $25,000 in funding and an allocation for compute to support early-stage development and feasibility testing. “Level-Up” Grant: $75,000 in funding and an allocation for compute to support more advanced development, such as demonstrating clinical performance, achieving model lock, or validating reproducibility. Additional rounds of funding and advanced computing resources will be available to further advance selected projects, including support for validation studies and external publication. "Oncology research is no longer bottlenecked solely by scientific hypotheses, but by immediate access to high-fidelity data and the massive computational power required to interpret it," said Ezra Cohen, MD, and Chief Medical Officer of Oncology at Tempus. "With the PRECISION Challenge, we are opening Tempus capabilities and allowing the broader research community to access the vast investments we have made in building our foundation model. We will embark on this effort collaboratively to address the fundamental questions in oncology that, before now, were impossible to address." Tempus will announce the opening of applications for the inaugural cohort of the PRECISION Challenge in the coming months. Researchers and investigators are encouraged to apply. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and benefits of Tempus’ PRECISION Challenge. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260530598089/en/ Tempus
Hanah Heintzelman
hanah.heintzelman@tempus.com Original: Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive ResultsMay 30, 2026 8:00 AM
Business Wire Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the introduction of Tempus Preview, an application providing rapid, clinically significant insights that close the gap between the time of order and delivery of insights. Representing a significant paradigm shift in precision oncology workflows, Tempus Preview offers preliminary results in the critical window between when a diagnostic test is ordered and when final sequencing results are delivered by surfacing key mutation predictions within approximately 24 hours of tissue receipt. The initial days following an advanced cancer diagnosis are critical for strategic treatment planning, yet clinicians have traditionally been forced to operate in an information vacuum while awaiting comprehensive genomic profiling results. Tempus Preview fundamentally redefines this diagnostic timeline. By combining Tempus’ multimodal data and advanced AI capabilities applied directly to the earliest touchpoints of the laboratory workflow, Tempus equips care teams to access early, clinically significant, information that can help inform complex decisions for patients and shorten the time between receipt of final molecular results and implementation of a personalized treatment plan. At launch, Tempus Preview will focus exclusively on high-impact biomarkers where early insights can be critical, including: Surfacing patients more likely to harbor microsatellite instability (MSI-H), a biomarker linked to improved response to immune checkpoint inhibitors and potential hereditary risk factors, in colorectal, endometrial, prostate, and esophagogastric cancers. Predicting EGFR mutations in non-small cell lung cancer (NSCLC), a biomarker that infers response to targeted therapy, but often lacks response to frontline immunotherapy. Highlighting increased probability of potential rare, yet clinically significant FGFR fusions in hepatobiliary and bladder cancers, that may indicate potential response to targeted therapy and improved patient prognosis if gene fusions are present. Shortly thereafter, Tempus Preview will expand to other critical biomarkers. Tempus Preview’s biomarker predictions are powered by Paige Predict, an advanced AI model that analyzes standard H&E images to provide genomic insights. Paige Predict, trained on millions of slides, has been validated for clinical use as part of Tempus’ laboratory-developed test. “At Tempus, our unique combination of a diagnostic lab and an advanced data platform enables us to build AI models powered by our unparalleled depth of real-world data,” said Eric Lefkofsky, Founder and CEO of Tempus. “That foundation creates a powerful flywheel: every insight strengthens our models, and every model helps generate more clinically meaningful insights for providers and patients. Tempus Preview brings this intelligence directly into the clinical workflow, delivering early, clinically relevant information within one day of sample receipt, which for many patients can mean the difference in how they are treated. This is our AI flywheel in action: transforming complex information into timely insights, delivered to physicians when they need them most.” Additional details on Tempus Preview can be found here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding potential impact of Tempus Preview. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260530829355/en/ Hanah Heintzelman
hanah.heintzelman@tempus.com Original: Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in OncologyMay 29, 2026 9:15 AM
Business Wire Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its mission to build Multimodal Foundation Models at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus has been building novel biological foundation models and agentic workflows by leveraging its more than 500 petabytes of rich, molecularly grounded data—more than 45 million total de-identified patient journeys, 1.5 million with sequenced data, and over 400,000 records in cancer with full genomic, transcriptomic, imaging, and clinical data. These efforts transform this data into unified patient representations, unlocking actionable insights to speed precision medicine efforts in both the clinic and drug development. Tempus’ latest multimodal, transformer-based model was trained on 2.5 million longitudinal records encapsulating more than 250 million pages of clinical notes, 450,000 digitized medical images, and 500,000 genomic and transcriptomic sequences. By aggregating modalities derived from billion-parameter foundation models, it is designed to address thousands of prediction objectives anchored in overall survival (OS) and progression-free survival (PFS), without requiring additional data or model fine-tuning. This architecture significantly reduces the time and data required to produce hundreds of clinically relevant insights for clinical trial design, patient risk prediction, and novel multimodal diagnostics. In a zero-shot setting without any further training, Tempus leveraged this patient trajectory model and a series of agentic workflows to unlock insights in a cohort of more than 1.2 million de-identified records with robust multimodal data. As a primary proof of concept, Tempus’ model was utilized to analyze EGFR-mutant NSCLC patients treated with osimertinib, the current frontline standard of care third-generation EGFR-inhibitor. Tempus assessed whether the model could accurately stratify response to the standard of care treatment of osimertinib in patients with known clinically actionable biomarkers like EGFR. This tests the model’s ability to learn a composite of features that predict response outside of known biological and clinical features to identify patients more likely to experience poor response to current therapies. Without any pre-specified training, the model demonstrated: Predictive Accuracy: A C-index of 0.802 for overall survival (p value < 0.001). Significant Survival Stratification: Hazard Ratio of 4.536 (95% CI: [3.289, 6.255]) between high- and low-risk subgroups. The model was evaluated against a range of mutation profiles (including more than 30 EGFR-specific features including L858R, Exon 19 del); and the results still produced prognostic value independent of molecular and clinical subgroups, significantly stratifying the overall survival of TP53(+) patients (HR=5.96), as well as progression-free survival in patients without CNS metastasis (HR=1.94). This outcome is just one example of how Tempus’ model can produce novel clinical insights, as similar results have been observed for predicting overall survival in other patient populations. Tempus’ multimodal patient trajectory models have also demonstrated substantial utility for drug development activities. For example, the models have successfully predicted outcomes of patient cohorts that mirrored pre-established clinical trials. In NSCLC, Tempus was able to assess cohorts mirroring those of practice-changing clinical trials (KEYNOTE-189, FLAURA-2, and DESTINY), and the multimodal patient trajectory model was able to zero-shot outperform standard approaches, such as Cox-PH modeling. These outcomes indicate substantial utility for biopharmaceutical developers, including the potential to assess features that may drastically impact clinical trial performance before a trial begins. "Foundation models, combined with agentic workflows, will help unlock the full potential of precision medicine — enabling rapid hypothesis testing and dramatically compressing the time from discovery to clinical application," said Eric Lefkofsky, Founder and CEO of Tempus. "The fact that our general purpose models are already outperforming highly tuned smaller models bodes well for the ability of our novel biological multimodal foundation models to improve clinical trial design and biomarker development, empowering physicians and life science companies in the pursuit of new diagnostics and novel medicines.” About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and benefits of Tempus’ suite of foundation models for insight generation into oncology. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260529085034/en/ Hanah Heintzelman
hanah.heintzelman@tempus.com Original: Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology

Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor PortfolioMay 29, 2026 8:15 AM
Business Wire Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. With this expanded label, Tempus is the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling. Tempus xT CDx is a 648-gene tissue-based assay intended for molecular profiling of all solid tumor malignancies. It also serves as a companion diagnostic to identify colorectal cancer patients who may benefit from targeted therapies, specifically Erbitux® (cetuximab) and Vectibix® (panitumumab). While xT CDx previously required a patient’s matched normal sample, this regulatory milestone allows the test to run as a tumor-only assay when a matched normal specimen (blood or saliva) is not viable or available. This approval paves the way for Tempus to migrate its entire DNA solid tumor portfolio to FDA-approved assays priced under its current ADLT (Advanced Diagnostic Laboratory Test) pricing. “This approval marks a milestone in both our regulatory and reimbursement strategy, as this allows the migration of our entire solid tumor DNA portfolio to be under unified ADLT pricing,” said Jim Rogers, Chief Financial Officer at Tempus. “As we have previously highlighted, we expect an estimated $200 ASP benefit beginning in 2027 as a result of this approval.” “Our goal is to support clinicians with advanced genomic profiling options,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “With FDA approval for both tumor-only and tumor-normal comprehensive genomic profiling, Tempus xT CDx provides flexibility for a range of clinical scenarios. While tumor-normal matched sequencing remains an important approach, we recognize that a matched sample is not always available, and now, patients can still benefit from an FDA-approved test that can help inform treatment decisions.” xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes in patients with previously diagnosed solid malignant neoplasms. The assay uses DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens and, when available, patient-matched blood or saliva specimens. Additionally, the device detects microsatellite instability (MSI) status based on a genomic signature from the tumor specimen only. The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling. Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product. Click to view the complete xT CDx label, including companion diagnostic indications and important risk information. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding potential impact of xT CDx and other tests, the timing of the availability of such testing, and the potential financial impact of migrating our solid tumor portfolio to FDA approved assays. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260529144345/en/ Tempus Communications
Hanah Heintzelman
hanah.heintzelman@tempus.com Tempus Investor Relations
Elizabeth Krutoholow
Elizabeth.krutoholow@tempus.com Original: Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio

Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical WorkflowsMay 27, 2026 8:33 AM
Business Wire Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a major technological upgrade to Tempus Hub, its AI-enabled smart physician platform. Tempus is making available its advanced, next-generation generative AI clinical co-pilot directly in Hub to power an agent-first experience for healthcare providers, allowing them to integrate the benefits of large language models and generative AI capabilities with their diagnostic results to better treat cancer patients This upgrade connects Tempus’ most advanced agentic AI capabilities directly with real-time patient data inside the Hub environment, scaling how providers utilize, interpret, and act upon complex diagnostic insights. Trusted by thousands of oncologists and care teams, Hub is a secure, AI-enabled platform that delivers actionable patient insights at the point of care. The platform provides seamless access to Tempus test orders and results, including guideline-matched therapies, treatment resistance insights, clinical trial opportunities, and longitudinal biomarker tracking for every patient. This new architecture introduces an advanced layer of agentic AI-enabled proactive intelligence. Key features rolling out to users include: Proactive AI Patient Genomic Insights: Hub can now proactively generate AI patient overviews and integrate deeper AI thinking applied to patients’ Tempus genomic results in the Hub summary page. Next-Step Documentation Generation: The platform is expanding to help users instantly generate patient-specific documentation, such as prior authorizations and patient messages, directly pulling in their Tempus data. Future Iterations of the Platform: Connecting Tempus Genomics Results with Tempus' Longitudinal Patient Registry or HIE (Health Information Exchange) data to unlock even more complex GenAI workflows. These capabilities are only possible given the significant investments Tempus has made over the years in building the foundation to connect AI to healthcare data, including (1) Edge, which allows for real-time connection to EHR data and other provider systems, (2) Locker, which allows providers to store their data in a secure environment they control as part of this connectivity; and (3) Air, which allows it to deploy AI models and algorithms in real time to deliver insights at the point of care. “Our evolution toward an agent-first experience within the Tempus Hub represents a massive win for clinical workflow efficiency,” said Shane Colley, Chief Technology Officer at Tempus. “By bringing our most sophisticated co-pilot intelligence directly into the Hub, we are unlocking the true power of multimodal data to provide seamless, on-demand decision support that meets providers exactly where they are." About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and benefits of Tempus’ integration of its advanced, next-generation generative AI clinical co-pilot directly in its smart physician platform, Hub. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260527419195/en/ Tempus
Hanah Heintzelman
hanah.heintzelman@tempus.com Original: Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows

Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial FrontsMay 19, 2026 8:55 AM
PR Newswire (US) Issued on behalf of Ventripoint Diagnostics Ltd.A Toronto-based small-cap is converting clinical validation into real-world hospital deployments at the moment AI cardiac imaging procurement is reorganizing globallyNEW YORK, May 19, 2026 /PRNewswire/ -- USA News Group News Commentary — Cardiology has become one of the proving grounds for medical artificial intelligence, and the procurement environment around it has shifted hard in the last twelve months. Hospital networks are no longer content to evaluate clinical accuracy in isolation; they want department-level economic proof before they sign deployment contracts. That shift is reshaping which AI imaging companies can convert pilot data into recurring revenue, and which cannot. The companies winning right now are the ones stacking regulatory clearances, commercial partnerships, and reimbursement-friendly clinical evidence at the same time. Industry forecasts help frame the prize at stake. The artificial intelligence in cardiology market has been projected to grow from approximately US$2.78 billion in 2026 to roughly US$14.22 billion by 2034, representing a compound annual growth rate near 22.6% over the period.[1] Echocardiography alone — the most widely used cardiac imaging modality in the world — is forecast to expand to US$2.64 billion by 2030 as health systems demand cardiac platforms that prove economic value alongside clinical accuracy.[2]Read the full report of Ventripoint here: USA News Group Ventrpoint CoveragePortable ultrasound, valued at roughly US$2.79 billion in 2026, is pushing cardiac assessment beyond the imaging lab and into point-of-care settings where speed and cost efficiency determine which technologies earn long-term hospital contracts.[3]Inside that environment, Ventripoint Diagnostics Ltd. (TSXV: VPT) (OTC: VPTDF) has spent the first half of 2026 stringing together exactly the kinds of validation events that the new procurement environment rewards.The Toronto-headquartered company applies proprietary Knowledge Based Reconstruction technology to standard 2D echocardiograms and produces volumetric cardiac measurements that the company describes as equivalent in accuracy to magnetic resonance imaging — and it does so on ultrasound systems that already sit in hospitals worldwide, regardless of vendor.A Regulatory Submission Into the World's Largest Cardiac Disease PopulationOn April 28, 2026, Ventripoint announced that its strategic partner Lishman Global Inc. had formally submitted the Company's VMS+ 4.0 system to China's National Medical Products Administration (NMPA) — the regulatory body commonly referred to as the Chinese FDA — for approval.[4] The filing is the principal regulatory gating event for VMS+ access to the Chinese cardiology market, and according to the Company, Lishman Global qualified for the NMPA's "green channel" pathway, an expedited review process designed for innovative medical technologies that address significant clinical needs.[4]The scale of the opportunity is difficult to overstate. The Company has cited an estimated 330 million cardiovascular disease patients in China, with cardiovascular disease the leading cause of mortality in the country.[4]Echocardiography is already the most widely used cardiac imaging modality in China because of its cost-effectiveness, portability, and scalability across both urban and rural healthcare settings.[4] What the market has been short on, in Ventripoint's framing, is the kind of AI-driven analytic layer that produces consistent, MRI-equivalent volumetric measurements from those existing ultrasound exams — particularly given variability in image interpretation across operators and limited access to advanced modalities like MRI in many parts of the country."China is one of the most important cardiac care markets in the world," said Hugh MacNaught, President and Chief Executive Officer of Ventripoint Diagnostics, in the announcement. "With the benefit of an expedited review pathway, we are well positioned to bring VMS+ 4.0 to clinicians and patients more quickly."[4] Paul Gibson, Chief Technology Officer of Lishman Global, added that qualification for the NMPA's green channel "underscores the clinical relevance and innovation of VMS+ 4.0 and provides a clear pathway to accelerated adoption."[4]Read the full report of Ventripoint here: USA News Group Ventrpoint CoverageBringing AI Cardiac Imaging Into a Padua-Based European CongressSix days after the NMPA submission was announced, Ventripoint disclosed plans to exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), held May 12–16, 2026 in Padua, Italy.[5] Founded in 1963, AEPC is described as the world's largest association in congenital cardiology, bringing together more than 1,000 specialists across 32 European countries.[5]The 2026 meeting was hosted by the University of Padova and featured a scientific program centred on advanced cardiovascular imaging and artificial intelligence — a fit, the Company argued, for what VMS+ is designed to deliver.[5]A central focus of Ventripoint's booth at AEPC was the use of VMS+ to support evolution of cardiac function over time in congenital heart disease (CHD) patients. The clinical rationale, as the Company described it, sits inside the 2020 ESC Guidelines for Adult Congenital Heart Disease — guidelines co-endorsed by AEPC — which identify CHD as a lifelong chronic condition requiring structured, individualised follow-up, and which affirm echocardiography as the key modality for longitudinal assessment of ventricular function.[5] The latest release, VMS+ 4.0, was purpose-built around the workflow needs of clinicians, the Company has said, streamlining the time required to generate assessments and making volumetric cardiac analysis accessible at the point of care.[5]"AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it," MacNaught said in the AEPC announcement. "VMS+ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI — giving clinicians the confidence they need to manage their patients at every stage of life."[5]A Wider Pattern of Validation Events Through Spring 2026The NMPA submission and AEPC exhibition are the two most recent links in a chain of events the Company has been building since the start of the year. Earlier in spring 2026, Ventripoint announced its Edison Award recognition, signed a commercial agreement with LG Consulting Solutions to support deployment of VMS+ across Northern California hospital systems, and announced a partnership delivering AI 3D heart mapping into Indigenous community settings through a Nisg_a'a partnership.[6]Considered together, those steps describe a small-cap AI medtech company simultaneously stacking validation across regulatory, commercial, and clinical fronts at the exact moment the broader hospital procurement environment is reorganizing around AI clinical solutions.[6]The LG Consulting Solutions agreement is structured precisely to address the financial proof requirement that has come to dominate hospital adoption decisions. Under the agreement, LG Consulting provides economic analysis, clinical implementation support, and health system business case development to assist hospitals and cardiac programs in adopting VentriPoint's AI-enhanced echocardiography technology.[6]In other words, the commercial framework on the ground in Northern California is designed to deliver department-level economic justification — which is exactly what hospital procurement is currently demanding before they sign.How Ventripoint Sits Inside a Reshaping Cardiac AI FieldVentripoint is far from the only public company chasing the AI cardiac imaging opportunity. Several larger names have moved aggressively across the past year — and the procurement environment for AI medtech is reshaping in real time as a result.Butterfly Network, Inc. (NYSE: BFLY) is one of the highest-profile names in handheld ultrasound. The Company has continued to expand integrations between its iQ family of probes and third-party AI cardiac applications, including the August 2025 announcement integrating Bordeaux-based DESKi's HeartFocus cardiac examination software into Butterfly's handheld devices — software that received FDA clearance in April 2025 and that allows healthcare professionals with minimal training to capture complete echocardiographic views.[7] Butterfly's strategy of partnering with AI cardiac software vendors places it in a structurally adjacent — but distinct — segment of the cardiac AI market from a knowledge-based reconstruction platform like Ventripoint's VMS+.Tempus AI, Inc. (NASDAQ: TEM) has been one of the cardiology AI sector's most-watched commercial stories. Tempus generated $1.2 billion in revenue for full-year 2025 and issued 2026 guidance of approximately $1.59 billion with around $65 million in adjusted EBITDA — projecting its first year of positive adjusted profitability.[1] Tempus's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatric care — a substantially broader footprint than a pure-play cardiac imaging company, but one that frames the institutional investor appetite for AI medical platforms more generally. RadNet, Inc. (NASDAQ: RDNT) has built one of the larger imaging-services-plus-AI businesses through its DeepHealth subsidiary. RadNet's recent acquisition of Gleamer — whose products are deployed in over 2,000 facilities across 30 countries — uniquely positions DeepHealth to expand its impact across routine imaging and accelerate the delivery of automated diagnostics, with the combined entity projected to generate approximately $30 million in annualized recurring AI revenue in 2026.[1] RadNet's scale on the imaging-services side gives it a different kind of moat than a pure software vendor — but the strategic message about AI moving from pilot to recurring revenue is the same one playing out across the sector.GE HealthCare Technologies Inc. (NASDAQ: GEHC) brings the perspective of one of the world's largest installed bases of cardiac imaging equipment. GE HealthCare has been advancing its own cardiac imaging capabilities through AI-powered reconstruction technologies — including AIR Recon DL and Sonic DL — designed to deliver diagnostic-quality cardiac MRI scans in significantly reduced timeframes.[1]The fact that the largest incumbent in the space is investing aggressively in AI-augmented cardiac imaging is, if anything, supportive of the thesis that AI-enhanced echocardiography platforms like Ventripoint's are arriving into a market actively being reorganized around AI-driven clinical workflows. Across all four comparables, the same pattern shows up: hospital systems are demanding economic proof, AI cardiac imaging is shifting from pilot to recurring revenue, and AI-augmented echocardiography is increasingly viewed as the most leverageable cardiac modality given its existing scale, portability, and cost profile.What Comes NextVentripoint's near-term catalysts are reasonably visible. The NMPA review process for VMS+ 4.0 in China is now underway, and the Company has said it will provide further updates as the review process progresses.[4] On the commercial side, the LG Consulting Solutions deployment partnership in Northern California is set up to convert clinical evidence into hospital-level economic justification.[6] On the European side, the AEPC exhibition in Padua delivered direct engagement with the largest concentration of paediatric and congenital cardiologists in Europe — a clinical community uniquely well-suited to longitudinal echocardiography-driven follow-up of complex patients.[5]The Company's stated 2026 priority is accelerating the integration of VMS+ into routine clinical practice and identifying opportunities to build better care pathways for CHD patients.[5]For investors tracking the cardiac AI sector, the Company offers a small-cap exposure to a corner of the AI medtech market where the procurement environment, the regulatory environment, and the clinical evidence base have all moved into alignment within the past six months. Whether that alignment translates into accelerating commercial momentum will be measured one deployment, one NMPA decision, and one congress at a time across the back half of 2026.Read the full report of Ventripoint here: USA News Group Ventrpoint CoverageCONTACT INFORMATION
USA News Group
info @therooster-2873Article Sources
[1] https://www.fortunebusinessinsights.com/ai-in-cardiology-market-115767 [2] https://www.marketresearch.com/Business-Research-Company-v4006/Cardiac-AI-Monitoring-Diagnostics-Global-44014609/ [3] https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-report [4] https://finance.yahoo.com/sectors/healthcare/articles/ventripoints-vms-tm-4-0-120000052.html [5] https://finance.yahoo.com/sectors/healthcare/articles/ventripoint-exhibit-59th-annual-meeting-132316747.html [6] https://www.globenewswire.com/news-release/2026/05/13/3294035/0/en/A-Toronto-AI-Cardiac-Diagnostics-Company-Just-Cleared-Three-of-the-Hardest-Validation-Bars-in-Medtech.html [7] https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-in-cardiology-market-reportDISCLAIMER NOTICENothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.Logo - https://mma.prnewswire.com/media/2838876/5656770/USA_News_Group_Logo.jpg View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiac-ai-diagnostics-stack-validation-wins-across-regulatory-and-commercial-fronts-302775850.htmlSOURCE USA News Group Original: Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts

Ambry Genetics’ CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”May 11, 2026 6:00 AM
Business Wire Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced that its CARE Program (Comprehensive, Assessment, Risk, and Education) has been awarded “Best Overall Health Informatics Solution” in the 10th Annual MedTech Breakthrough Awards. The global program recognizes excellence in digital health and medical technology, selecting CARE from more than 5,000 nominations worldwide. The CARE program is a best-in-class, EHR-integrated digital risk assessment program designed to help health systems identify patients at increased risk for breast cancer or who otherwise qualify for hereditary cancer testing. By utilizing a suite of digital tools embedded directly into existing clinical workflows, the CARE program identifies at-risk patients and provides them with personalized education while streamlining the entire genetic test ordering and results process for providers. This proactive approach helps clinicians understand a patient’s risk before the visit, enabling personalized care and earlier cancer detection through advanced screening. By directly connecting patients with certified genetic counselors, the program delivers an end-to-end model that makes genetic care more proactive, standardized, and equitable. “CARE has fundamentally changed how we care for patients at risk,” said Kevin M. Banks, Ph.D., Executive Director of Precision Health at The Christ Hospital Health Network. “It simplifies what used to be a 'process' by seamlessly integrating patient education and gives our clinicians critical insights when they matter most. CARE has not only smoothed our workflows but has also made a real difference in determining patient care." “Receiving this award alongside other industry leaders highlights the importance of integrating genetic insights directly into everyday clinical care to improve outcomes for high-risk patients,” said Tom Schoenherr, CEO of Diagnostics at Tempus. “CARE exemplifies Ambry’s commitment to streamlining clinical workflows and enabling providers to deliver more proactive, personalized care. We are incredibly proud of the impact CARE has already made, and will continue to make, in advancing care for high-risk patients.” About Ambry Genetics ® Ambry Genetics, a wholly owned subsidiary of Tempus, translates scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. It is a leader in genetic testing and aims to improve health by understanding the relationship between genetics and disease. Over its 25-year history, Ambry has remained committed to empowering patients to make informed healthcare decisions based on their genetic data. About TEMPUS ® Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com. FORWARD LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of Ambry Genetics research and publications; the contributions of Ambry Genetics research and findings to the larger scientific community and the use of its products and services to advance clinical care for patients are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260511292359/en/ For Ambry Genetics
media@tempus.com Original: Ambry Genetics’ CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”

Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior NotesMay 8, 2026 12:59 AM
Business Wire Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $400.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the Offering was increased from the previously announced offering size of $350.0 million. Tempus also granted the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $60.0 million aggregate principal amount of Notes. The sale of the Notes to the initial purchasers is expected to close on May 12, 2026, subject to customary closing conditions. The Notes will be general unsecured obligations of Tempus and will not bear regular interest and the principal amount of the notes will not accrete. The Notes will mature on May 15, 2032, unless earlier converted, redeemed or repurchased. Tempus estimates that the net proceeds from the Offering will be approximately $384.1 million (or approximately $441.9 million if the initial purchasers exercise their option to purchase additional Notes in full), after deducting the initial purchasers’ discounts and commissions and estimated Offering expenses payable by Tempus. Tempus expects to use the net proceeds from the Offering to repay in full $307.7 million of outstanding loans under its senior secured credit facilities, plus accrued and unpaid interest and other fees, to pay the approximately $27.2 million cost of the capped call transactions described below, and for general corporate purposes, which may include acquisitions or strategic investments in complementary businesses or technologies, working capital, operating expenses, capital expenditures and repayment of additional indebtedness. If the initial purchasers exercise their option to purchase additional Notes, Tempus expects to use a portion of the net proceeds from the sale of the additional Notes to enter into additional capped call transactions and for the general corporate purposes described above. Noteholders may convert all or any portion of their Notes at their option at any time prior to the close of business on the business day immediately preceding February 15, 2032 only if one or more specific conditions are met. On or after February 15, 2032 until the close of business on the second scheduled trading day immediately preceding the maturity date, the Notes will be convertible in integral multiples of $1,000 principal amount at the option of the noteholders at any time regardless of these conditions. Upon conversion, Tempus will pay or deliver, as the case may be, cash, shares of Tempus’ Class A common stock, par value $0.0001 per share (the “Class A common stock”) or a combination of cash and shares of Class A common stock, at its election. The conversion rate will initially be 14.4388 shares of Class A common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $69.26 per share of Class A common stock, which represents a conversion premium of approximately 40% to the last reported sale price of the Class A common stock on the Nasdaq Global Select Market on May 7, 2026). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid special interest, if any. In addition, following certain corporate events that occur prior to the maturity date of the Notes or if Tempus delivers a notice of redemption, Tempus will, in certain circumstances, increase the conversion rate of the Notes for a noteholder who elects to convert its Notes in connection with such a corporate event or convert its Notes called (or deemed called) for redemption during the related redemption period, as the case may be. Tempus may not redeem the Notes prior to May 21, 2029. Tempus may redeem for cash all or any portion of the Notes (subject to the partial redemption limitation described below), at its option, on a redemption date on or after May 21, 2029 if the last reported sale price of the Class A common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which Tempus provides notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid special interest, if any, to, but excluding, the redemption date. If Tempus redeems fewer than all of the outstanding Notes, at least $75 million aggregate principal amount of Notes must be outstanding and not subject to redemption as of, and after giving effect to, delivery of the relevant notice of redemption. If Tempus undergoes a “fundamental change” (as defined in the indenture that will govern the Notes), then, subject to certain conditions and limited exceptions, noteholders may require Tempus to repurchase for cash all or any portion of their Notes in principal amounts of $1,000 or an integral multiple thereof at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid special interest, if any, to, but excluding, the fundamental change repurchase date. In connection with the pricing of the Notes, Tempus entered into privately negotiated capped call transactions with one of the initial purchasers or its affiliate and other financial institutions (the “Option Counterparties”). The capped call transactions cover, subject to customary adjustments, the number of shares of Class A common stock initially underlying the Notes. The capped call transactions are expected generally to reduce the potential dilution to the Class A common stock upon any conversion of Notes and/or offset any cash payments Tempus is required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the capped call transactions relating to the Notes will initially be $98.94, which represents a premium of 100% over the last reported sale price of the Class A common stock on the Nasdaq Global Select Market on May 7, 2026, and is subject to certain adjustments under the terms of the capped call transactions. In connection with establishing their initial hedges of the capped call transactions, Tempus expects the Option Counterparties or their respective affiliates will enter into various derivative transactions with respect to the Class A common stock and/or purchase shares of Class A common stock concurrently with or shortly after the pricing of the Notes, including with, or from, as the case may be, certain investors in the Notes. This activity could increase (or reduce the size of any decrease in) the market price of the Class A common stock or the Notes at that time. In addition, the Option Counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to the Class A common stock and/or purchasing or selling Class A common stock or other securities of Tempus in secondary market transactions following the pricing of the Notes and prior to the maturity of the Notes (and are likely to do so during the 20 trading day period beginning on the 21st scheduled trading day prior to the maturity date of the Notes, or, to the extent Tempus exercises the relevant election under the capped call transactions, following any repurchase, redemption or conversion of the Notes). This activity could also cause or avoid an increase or a decrease in the market price of the Class A common stock or the Notes which could affect a noteholder’s ability to convert the Notes and, to the extent the activity occurs during any observation period related to a conversion of Notes, it could affect the number of shares, if any, and value of the consideration that a noteholder will receive upon conversion of its Notes. The Notes and any shares of Class A common stock issuable upon conversion of the Notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws. This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the proposed Offering, including statements concerning the proposed terms of the Notes and the capped call transactions, the anticipated completion, timing and size of the proposed Offering of the Notes and the capped call transactions, the anticipated use of proceeds from the Offering, and the potential impact of the foregoing or related transactions on dilution to holders of the Class A common stock and the market price of the Class A common stock or the Notes or the conversion price of the Notes. These forward-looking statements are based on Tempus’ current assumptions, expectations and beliefs and are subject to substantial risks, uncertainties, assumptions and changes in circumstances that may cause Tempus’ actual results, performance or achievements to differ materially from those expressed or implied in any forward-looking statement. These risks include, but are not limited to market risks, trends and conditions. These and other risks are more fully described in Tempus’ filings with the Securities and Exchange Commission (“SEC”), including in the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as well as other filings Tempus may make with the SEC in the future. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260507350635/en/ Tempus Communications
Hanah Heintzelman
media@tempus.com Tempus Investor Relations
Elizabeth Krutoholow
Elizabeth.krutoholow@tempus.com Original: Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest ExpenseMay 7, 2026 7:11 AM
Business Wire - Proceeds expected to be used to repay in full outstanding loans under the senior secured credit facilities, reducing interest expense and enhancing financial flexibility. Additional proceeds expected to be used to pay for capped call transactions to reduce potential dilution and for general corporate purposes. Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $350.0 million aggregate principal amount of Convertible Senior Notes due in 2032 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Tempus also intends to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $52.5 million aggregate principal amount of Notes. The Notes will be general unsecured obligations of Tempus, will accrue interest payable semiannually in arrears and will mature on May 15, 2032, unless earlier converted, redeemed or repurchased. Upon conversion, Tempus will pay or deliver, as the case may be, cash, shares of Tempus’ Class A common stock, par value $0.0001 per share (the “Class A common stock”), or a combination of cash and shares of Class A common stock, at its election. The interest rate, initial conversion rate and other terms of the Notes will be determined at the time of pricing of the Offering. Tempus expects to use the net proceeds from the Offering to repay in full $307.7 million of outstanding loans under its senior secured credit facilities, plus accrued and unpaid interest and other fees, to pay the cost of the capped call transactions described below and for general corporate purposes, which may include acquisitions or strategic investments in complementary businesses or technologies, working capital, operating expenses, capital expenditures and repayment of additional indebtedness. If the initial purchasers exercise their option to purchase additional Notes, Tempus expects to use a portion of the net proceeds from the sale of the additional Notes to enter into additional capped call transactions and for the general corporate purposes described above. In connection with the pricing of the Notes, Tempus expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or affiliates thereof and/or other financial institutions (the “Option Counterparties”). The capped call transactions will cover, subject to customary adjustments, the number of shares of Class A common stock initially underlying the Notes. The capped call transactions are expected generally to reduce the potential dilution to the Class A common stock upon any conversion of Notes and/or offset any cash payments Tempus is required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap. In connection with establishing their initial hedges of the capped call transactions, Tempus expects the Option Counterparties or their respective affiliates will enter into various derivative transactions with respect to the Class A common stock and/or purchase shares of Class A common stock concurrently with or shortly after the pricing of the Notes, including with, or from, as the case may be, certain investors in the Notes. This activity could increase (or reduce the size of any decrease in) the market price of the Class A common stock or the Notes at that time. In addition, the Option Counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to the Class A common stock and/or purchasing or selling Class A common stock or other securities of Tempus in secondary market transactions following the pricing of the Notes and prior to the maturity of the Notes (and are likely to do so during the 20 trading day period beginning on the 21st scheduled trading day prior to the maturity date of the Notes, or, to the extent Tempus exercises the relevant election under the capped call transactions, following any repurchase, redemption or conversion of the Notes). This activity could also cause or avoid an increase or a decrease in the market price of the Class A common stock or the Notes which could affect a noteholder’s ability to convert the Notes and, to the extent the activity occurs during any observation period related to a conversion of Notes, it could affect the number of shares, if any, and value of the consideration that a noteholder will receive upon conversion of its Notes. The Notes and any shares of Class A common stock issuable upon conversion of the Notes have not been and will not be registered under the Securities Act, any state securities laws or the securities laws of any other jurisdiction, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws. This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the proposed Offering, including statements concerning the proposed terms of the Notes and the capped call transactions, the anticipated completion, timing and size of the proposed Offering of the Notes and the capped call transactions, the anticipated use of proceeds from the Offering, the impact of the Offering on Tempus’ future interest expense and financial flexibility, and the potential impact of the foregoing or related transactions on dilution to holders of the Class A common stock and the market price of the Class A common stock or the Notes or the conversion price of the Notes. These forward-looking statements are based on Tempus’ current assumptions, expectations and beliefs and are subject to substantial risks, uncertainties, assumptions and changes in circumstances that may cause Tempus’ actual results, performance or achievements to differ materially from those expressed or implied in any forward-looking statement. These risks include, but are not limited to market risks, trends and conditions. These and other risks are more fully described in Tempus’ filings with the Securities and Exchange Commission (“SEC”), including in the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as well as other filings Tempus may make with the SEC in the future. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260506244818/en/ Tempus Communications
Hanah Heintzelman
media@tempus.com Tempus Investor Relations
Elizabeth Krutoholow
Elizabeth.krutoholow@tempus.com Original: Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

Tempus AI Shares Gain After Expanded Partnership with GileadApril 10, 2026 9:34 AM
IH Market News
Shares of Tempus AI Inc. (NASDAQ:TEM) climbed 3% on Friday morning after the company announced an expanded multi-year collaboration with Gilead Sciences Inc. (NASDAQ:GILD), aimed at supporting the development of Gilead’s oncology pipeline.The new agreement grants Gilead enterprise-wide access to Tempus’ AI-powered Lens platform, which offers expanded datasets across various disease areas along with dedicated analytical support. Gilead has already been utilizing Tempus’ anonymized multimodal data for oncology research, including applications in clinical trial design, indication selection, biomarker development, health outcomes analysis, and real-world evidence generation.As part of the enhanced partnership, Gilead will use Tempus’ multimodal data resources to generate insights intended to guide clinical decision-making in cancer care.“By providing access to the Tempus multimodal data library, we are empowering the Gilead team to further fuel its R&D engine with AI-driven insights,” said Ryan Fukushima, CEO of Tempus Data & Apps. “We are thrilled to expand this collaboration, offering the multimodal depth necessary to uncover critical biological insights.”Tempus AI is a technology firm focused on applying artificial intelligence to advance precision medicine through its data and analytics platforms.

Original: Tempus AI Shares Gain After Expanded Partnership with Gilead

Tempus to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 4:01 PM
Business Wire
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16.


Tempus’ Chief Financial Officer Jim Rogers, will participate in a fireside discussion at the conference on Tuesday, April 14 at 11:45 am ET. A live webcast of the conversation will be available here.


About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260408327074/en/
Tempus

Hanah Heintzelman

Hanah.heintzelman@tempus.com


Original: Tempus to Present at the 25th Annual Needham Virtual Healthcare Conference

Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve OutcomesMarch 3, 2026 12:19 PM
PR Newswire (US)

Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 3, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — AI is making its way through the halls of our entire medical system, and the implementation is accelerating at a great pace. The AI medical imaging market is projected to hit nearly $20 billion by 2033, growing at a 34.7% CAGR[1]. Echocardiography alone is forecast to grow to $2.64 billion by 2030 as hospitals demand cardiac platforms that prove economic value alongside clinical accuracy[2]. Companies like VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Butterfly Network (NYSE: BFLY), Tempus AI (NASDAQ: TEM), RadNet (NASDAQ: RDNT), and GE HealthCare (NASDAQ: GEHC) are converting clinical validation into contracted hospital deployments.







Digital diagnostics platforms are projected to reach $7.67 billion by 2035 at an 18.12% CAGR as health systems shift from evaluating clinical capability to requiring department-level financial proof before adoption[3]. Portable ultrasound, valued at $2.79 billion in 2026, is pushing cardiac assessment beyond traditional imaging labs and into point-of-care settings where speed and cost efficiency determine which technologies earn long-term hospital contracts[4].VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) recently signed a commercial agreement with LG Consulting Solutions to support deployment of its VMS+™ system across Northern California. Under the agreement, LG Consulting will provide economic analysis, clinical implementation support, and health system business case development to assist hospitals and cardiac programs in adopting VentriPoint's AI-enhanced echocardiography technology. The collaboration will focus on demonstrating the economic and clinical value of VMS+™ imaging and workflow integration across healthcare systems in the Sacramento and San Francisco regions.As part of the agreement, LG Consulting Solutions is purchasing a VMS+™ system for deployment as a demonstration platform to support hospital engagement, clinician training, and economic value assessments. The agreement also includes the potential for revenue sharing related to 3D echocardiography processing services."Economic and operational clarity are critical to accelerating the adoption of new medical technologies," said Hugh MacNaught, President and CEO of VentriPoint Diagnostics. "This collaboration will help hospitals clearly evaluate how VMS+™ can improve cardiac care pathways, enhance clinical insight into cardiac function, and support better patient care while delivering measurable value to healthcare systems."Northern California represents an important market for VentriPoint given its concentration of leading cardiac centers and healthcare systems focused on improving cardiovascular outcomes."Healthcare systems increasingly require clear clinical and economic evidence before adopting new technologies," said Lori Gallian, Principal of LG Consulting. "Through this collaboration, we will work directly with cardiac programs to develop practical implementation strategies and demonstrate how VMS+™ can deliver both clinical and operational benefits."CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint In other industry developments and happenings in the market include:Butterfly Network (NYSE: BFLY) recently reported fourth quarter 2025 revenue of $31.5 million, a 41% increase year-over-year, while generating positive operating cash flow for the first time in the company's history. Full-year 2025 revenue reached $97.6 million, up 19% from the prior year. The company also launched Compass, its AI-powered clinical decision support system designed to guide clinicians through point-of-care ultrasound exams." Nearly two years into our strategic plan, we are executing with financial discipline, strengthening our core point-of-care business, and now realizing material organic revenue from new initiatives," said Joseph DeVivo, CEO of Butterfly Network. "From expanding enterprise adoption in point-of-care, to building HomeCare into a commercial business, to enabling entirely new applications through Butterfly Embedded, it's all powered by the same proprietary Ultrasound-on-Chip™ technology. One platform and one diversified strategy that puts us in a strong position to execute and win."The company issued 2026 revenue guidance of $117 million to $121 million, representing 20% to 24% growth. Butterfly's handheld ultrasound platform is used across emergency, primary care, and critical care settings, expanding cardiac and vascular assessment beyond traditional imaging labs.Tempus AI (NASDAQ: TEM) recently reported fourth quarter 2025 revenue of $367.2 million, an 83% increase year-over-year. For the full year, Tempus generated $1.2 billion in revenue and issued 2026 guidance of approximately $1.59 billion with around $65 million in adjusted EBITDA, projecting its first year of positive adjusted profitability."In 2025, Tempus continued to set the standard for what it means to be a technology company operating in the healthcare space," said Eric Lefkofsky, Founder and CEO of Tempus. "The strength of our unit growth in diagnostics along with the accelerating growth of our data business is proof that we are unique in this space. As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years, but to also enhance the lives of millions of patients around the world."The company's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatry. Tempus serves more than 50% of U.S. oncologists and is expanding its data licensing and clinical trial matching capabilities into cardiovascular diagnostics.RadNet (NASDAQ: RDNT) recently acquired Gleamer, a Paris-based pioneer in AI-powered medical imaging, for up to €230 million. The acquisition positions RadNet's DeepHealth subsidiary as the largest radiology-focused clinical AI provider worldwide, combining Gleamer's BoneView and ChestView FDA-cleared algorithms with DeepHealth's existing suite of mammography, lung, and prostate AI solutions."As imaging volumes continue to rise amid an accelerating shortage of radiologists worldwide, reengineering high-volume workflows — particularly routine imaging such as X-ray, ultrasound and mammography — is becoming essential to sustaining access, efficiency and quality of care," said Dr. Howard Berger, President and CEO of RadNet. "For radiologists and providers, the key lies in advancing automated exam prioritization and draft reporting. The acquisition of Gleamer uniquely positions DeepHealth to expand its impact across routine imaging and high-impact acute diagnostic care and accelerate the delivery of automated diagnostics."Gleamer's products are deployed in over 2,000 facilities across 30 countries. The combined entity is projected to generate approximately $30 million in annualized recurring AI revenue in 2026, with commercial deployment spanning bone fracture detection, chest pathology screening, and advanced mammography analytics.GE HealthCare (NASDAQ: GEHC) recently announced the first implementation of its SIGNA Sprint Elite MRI system at Inova Health System. The platform integrates advanced cardiac imaging capabilities with AI-powered reconstruction technologies including AIR Recon DL and Sonic DL, designed to deliver diagnostic-quality cardiac MRI scans in significantly reduced timeframes."Achieving FDA clearance of our next-generation SIGNA MRI technology underscores our commitment to expanding access to high-quality imaging and elevating the standard of care for patients everywhere," said Kelly Londy, President and CEO, MR at GE HealthCare. "As MRI demand continues to rise across clinical areas, providers need solutions that deliver greater efficiency without compromising diagnostic precision. With this new SIGNA generation, we're redefining what's possible – aiming to bring smarter, faster, more sustainable and more consistent imaging to more patients, across more settings, with confidence."The SIGNA Sprint Elite features a compact 22-square-meter footprint, allowing installation in outpatient and community settings previously limited to basic imaging. GE HealthCare's broader imaging portfolio serves more than 1 billion patients annually across 160 countries, with its MR division focused on expanding AI-integrated cardiac and neurological imaging platforms.Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint CONTACT:USA NEWS GROUPinfo @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. ("BAY") There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-medical-imaging-markethttps://www.precedenceresearch.com/echocardiography-markethttps://www.towardshealthcare.com/insights/digital-diagnostics-system-market-sizinghttps://www.towardshealthcare.com/insights/portable-ultrasound-market-sizingLogo: https://mma.prnewswire.com/media/2838876/5833576/USA_News_Group_Logo.jpg



View original content to download multimedia:https://www.prnewswire.com/news-releases/hospital-networks-turn-to-ai-enhanced-cardiac-imaging-to-cut-costs-and-improve-outcomes-302702775.html

Original: Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision MedicineMarch 3, 2026 8:30 AM
Business Wire
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck’s oncology and potentially broader therapeutic portfolios.


“This collaboration builds on our existing relationship and reflects our shared commitment to harnessing the power of multimodal datasets with AI to deliver better options for patients,” said Ryan Fukushima, CEO, Data & Apps at Tempus. “We’ve spent years configuring our Lens Platform to seamlessly leverage our library of de-identified multimodal data with the necessary AI computing power to train and fine-tune specific models for healthcare. Working with the great scientists at Merck, we have exciting opportunities to translate the insights from AI models into precision medicine strategies and improve patient outcomes across oncology and beyond.”


Under the terms of the agreement, Merck will use Tempus’ de-identified data along with Tempus’ Lens Platform and Workspaces environment, which offers an advanced computational configuration powered by one of the industry’s largest GPU infrastructures, which enables researchers to efficiently conduct complex analyses on training-ready multimodal datasets, generating novel insights to accelerate the development and optimization of candidate therapies at scale.


“The combination of new AI technologies and large curated multimodal data sets are transforming the way we conduct discovery research,” said George Addona, Senior Vice President, Discovery, Preclinical Development and Translational Medicine, Merck Research Laboratories. “This collaboration with Tempus positions Merck to advance our precision oncology strategy through the application of the latest AI/ML capabilities to discover novel precision biomarkers, identify mechanisms of cancer cell resistance, and inform rational combinations for drugs in our early pipeline.”


About Tempus


Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.


Forward Looking Statements


This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and benefits of Tempus’ collaboration with Merck to accelerate AI driven medicine and biomarker discovery in oncology. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.


You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260303796307/en/
Tempus

Hanah Heintzelman

Hanah.heintzelman@tempus.com


Original: Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

Thanks. $120 by Xmas 😃

Congrats on you hitting the target in dead center!

TEM on Ascending Triple Top Breakout since 7-Oct-2025, yesterday. GLTA

~bought some 8/15 $90 calls @.08c

Tempus AI  ...Duh
https://www.cms.gov/newsroom/press-releases/white-house-tech-leaders-commit-create-patient-centric-healthcare-ecosystem

So would I

Still hodling 🫠

https://sherwood.news/markets/tempus-ai-hammered-by-short-sellers-report/

Today was a great buying opportunity to buy buy buy 😃
Professional Short seller Spruce point capital put out a ludicrous hit piece on Tempus and apparently it shook up investors. Lol.
Thank you for your shares 😃

DCA people,, 
There's still time for you 🙏 

$100 by summer ☀️ 

Should be great tomorrow.. Come back guys.. not too late to jump back in.

Another fantastic day.. Except for the panic sellers 😢 

Fantastic day. Too bad everyone panic sold 😪 

Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and servicesAnnounced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next 3 yearsIncreasing full year 2025 revenue guidance to $1.25 billion, representing approximately 80% growth year-over-year. Expect positive Adjusted EBITDA of $5 million for full year 2025, increasing approximately $110 million over 2024https://www.businesswire.com/news/home/20250506572067/en/Tempus-Reports-First-Quarter-2025-Results

https://finance.yahoo.com/news/tempus-report-first-quarter-2025-123000132.html

Exactly.....

Whales know this game well. 

Oh wait after hours, back to 45 per share. That's funny. 100% millionaires & institutional gamblers flipping this stock to take retail money piece by piece, one family wealth portfolio at a time lol

Of course after a dump to 44 it goes back to 52 lol....
This is what you call millionaires flipping

Garbage ticker... They pump it up to 60 with news and Twitter clowns and then drop it 25% as they cash out. Mind you, look at the Insider activity over the past few months, they tend to dump shares often. 
"Break through AI" "Revolutionary" "Cathy Woods, Nansi Pelosi" this the and the next bull$hit story.. and then everyday, share price dumping 2% to 5%... They pumped it to create liquidity to dump shares on Retail... Quit Stocks, invest in yourself and your family is my advice.

This is a ponzy

Now think, what is the value of chasing Nancy Paloci, Cathy Woods, and other institutional investors into tickers... Retail is the liquidity lol... Ya'll need to figure that part out 

It's over rover... Fun times done. Now for profit taking on the AI over-Hyped Ponzy scheme

Now it looks like millionaires, billionaires and Company executives are taking profits while retail is giving them the liquidity to do so. 
Lol

F**CK This stock lol..... Thankfully, I'm only down a couple percent but time to go back to Crypto today i guess

https://finance.yahoo.com/news/tempus-ai-inc-tem-among-034950522.html
We recently published a list of Cathie Wood’s Top 12 AI Stock Picks in 2025. In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) ...

Getting loaded up

https://www.tipranks.com/news/cathie-wood-capitalizes-on-pullback-in-tempus-ai-to-buy-additional-stock-worth-14-4m

https://www.entrepreneur.com/finance/tempus-ai-is-a-buy-if-you-can-handle-the-volatility/487637

 🚀  🌛 

TEM, 10 Q due MONDAY 2/24

Started buying her at 25.00 when everyone thought the buyout on AI healthcare app was a bad idea. Always buy the fear. Holding 100.00+
easy 5x ROI

Need a Moderator